MicroPort MedBot Receives NMPA Approval for UniPath Bronchoscopic Surgical Robot, Becomes First Company to Commercialize Full Spectrum of Robotic Surgery Systems
核心洞察
Shanghai MicroPort MedBot (搜索) has received NMPA approval for its UniPath Electronic Bronchoscopic Surgical Robotic System, designed for early diagnosis and treatment of deep and peripheral pulmonary lesions.
The approval brings the company's portfolio to seven approved surgical robot products, making it the first enterprise globally to commercialize robotic systems across five major surgical specialties.
UniPath features an ultra-compliant, ultra-slim snake-like robotic catheter that can access hard-to-reach lesions through natural body pathways without surface incisions.
Shanghai MicroPort MedBot (搜索) (Group) Co., Ltd. has achieved a significant regulatory milestone with the approval of its UniPath Electronic Bronchoscopic Surgical Robotic System by China's National Medical Products Administration (NMPA). This approval marks the company as the first enterprise globally to commercialize a full spectrum of robotic systems across five major surgical specialties, bringing its total portfolio of approved surgical robot products to seven.
Revolutionary Non-Invasive Platform Technology
The newly approved UniPath represents a breakthrough in non-invasive natural orifice robotic surgery platforms. The system features an ultra-compliant, ultra-slim snake-like robotic catheter capable of accessing hard-to-reach narrow lesion spaces through the body's natural pathways without requiring any surface incisions. This technological advancement holds significant importance for the early diagnosis and treatment of small pulmonary nodules and other early-stage cancerous changes.
As a typical representative of natural orifice surgical robots, the bronchoscopic surgical robot is considered a critical technological pathway driving the evolution of minimally invasive surgery toward "less trauma and no external incisions." In recent years, it has become one of the fastest-growing intelligent minimally invasive diagnosis and treatment platforms in the field of respiratory intervention.
Advanced System Integration and Capabilities
At the system level, UniPath integrates key technologies including precise robotic control, flexible catheter navigation, intelligent path planning, and closed-loop control, providing a comprehensive solution tailored to complex pulmonary anatomical environments. The system is centered on four core capabilities: "full-lung accessibility, real-time visualization, accurate targeting, and stable operation."
The platform enhances access to fine bronchi and deep lung segments through multi-layered synergy among instruments, navigation, imaging, and control. It supports higher certainty in reaching and performing puncture and ablation procedures on deep and peripheral small lesions under dynamic respiratory conditions, continuously expanding the clinical application boundaries of bronchoscopic interventions.
Market Leadership and Ecosystem Development
The NMPA's approval of UniPath marks a milestone breakthrough for MicroPort MedBot (搜索) in leading the technological and application development of global surgical robots. It also signifies that domestically produced surgical robots have achieved systematic full coverage of key technologies in minimally invasive diagnosis and treatment.
The company's achievement in becoming the world's first and currently only company to commercialize products across all five major surgical robot segments demonstrates its comprehensive technological capabilities. A domestic surgical robot ecosystem, continuously constructed by the group with systematic innovation at its core and platform-based capability output as support, is characterized by system integrity, technical depth, and sustainable evolution, and is rapidly taking shape while entering a phase of scaled development.
Clinical Significance for Pulmonary Medicine
The UniPath system is specifically designed for early diagnosis and treatment of deep and peripheral pulmonary lesions such as micronodules. This capability addresses a critical need in respiratory medicine, where early detection and intervention of small pulmonary lesions can significantly impact patient outcomes. The system's ability to navigate complex pulmonary anatomy while maintaining precision represents a significant advancement in bronchoscopic intervention technology.